The substrate requirements for angiotensin I-converting enzyme were studied in vivo in the dog lung and in vitro in plasma, using angiotensin I (AI), 5-D-Ile-AI, 7-D-Pro-AI, and 8-r>Phe-AI which had been synthesized by the solid-phase technique. All peptides were inactive in the rabbit aortic strip preparation. None of the D-amino acid-substituted peptides gave a pressor response in the anesthetized dog; none showed significant immunologic cross-reactivity with anti-AI serum or antiangiotensin II serum. Each peptide was labeled with 125 I, and the monoiodinated species was isolated. The iodinated peptides were incubated with diluted dog plasma or injected into the right ventricle of intact anesthetized dogs. In vitro, 125 I-AI, 125
I-7-r>Pro-AI into the right ventricle, 125 I-AII accounted for 70, 60, and 45%, respectively, of the radioactive material in aortic blood. These results and our previous observations on the importance of the C-terminal sequence of AI for conversion indicate that the enzymatic binding sites for Al-converting enzyme in vivo and in vitro extend from position 10 to position 8 but not to position 7. D-amino acid substitution at positions 7 and 5 abolishes biologic and immunologic activity without interfering with conversion.
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• Conversion of angiotensin I (AI) to angiotensin II (All) occurs in vivo in the pulmonary capillary bed and in vitro in plasma via a dipeptidylcarboxypeptidase (1) (2) (3) (4) . Substitution of a D-amino acid at the C-terminus or deletion of the C-terminal amino acid of AI prevents conversion (1) , emphasizing the importance of the C-terminal sequence of AI for the specificity of Al-converting enzyme. In the present study, synthetic AI analogues containing Damino acid substitutions within the sequence of AH were used to further characterize the conversion of AI to All in plasma and in the pulmonary circulation of the intact dog. was added, and the mixture was allowed to react for 1 minute at room temperature. Then 20 //.liters of a 0.4-mg/ml solution of Na 2 S 2 O 5 was added. The mixture was applied immediately to a 0.9 X 100-cm column of DEAE Sephadex A-25. The column was developed with O.IN sodium phosphate buffer, pH 7.4, at room temperature. A 5-//Jiter sample of each 3-ml fraction of column eluate was counted.
The results of a typical iodination procedure, performed in this case on AI, are shown in Figure 1 . Over 95% of the labeled material eluted from the column was monoiodinated AI. Similar elution profiles were obtained for the analogues of AI. Estimated specific activity of the monoiodinated species was 700 me///.mole. The monoiodinated peptides were either used immediately or frozen with lysozyme (1 mg/ml) and stored at -20°C.
PREPARATION OF PEPTIDE STANDARDS
To develop a system for distinguishing generated All from AI and from the products of other circulating enzymes, peptide standards were prepared. Monoiodinated AI, All, D-Phe-AI, D-Pro-AI, and D-Ile-AI were incubated with trypsin, chymotrypsin, or leucine aminopeptidase (Worthington). Figure 2 summarizes the cleavages which are expected to occur with the three enzymes. To generate D-amino acid-substituted All, D-Phe-AI was incubated with carboxypeptidase A. All enzyme incubations were carried out in a volume of 2 ml containing 4 pmoles (4 X 10 6 counts/min) of 125 I-AI at 37°C. Preliminary experiments in which samples of the reaction mixtures were removed at frequent intervals and analyzed indicated that the reactions went to completion in the incubation periods that were chosen. Each reaction mixture was divided into aliquots and either frozen on acetone and Dry Ice and stored at -20°C or spotted on Whatman 3MM paper and subjected to electrophoresis (Savant Company) at 4,000 v for 1 hour in pyridine acetate buffer at pH 3.55. The paper was dried, cut into 1-cm strips, and counted in a gamma counter (Nuclear Chicago). The stored samples were thawed and passed through a 0.9 X 100-cm column of DEAE Sephadex A-25 which was developed by the technique previously described for purification of iodinated peptides. Figure 3 shows the clear separation of standard 125 I-AI from 125 I-AII by electrophoresis and column chromatography. Figure 4 summarizes the separation of the peptide fragments of 125 I-AI from one another and from AI and AIL All of the D-amino acid analogues of AI, D-Phe-AII, and the small peptide fragments containing D-amino acids behaved the same as did the corresponding all-L peptides in both systems. When analyzed by both techniques, all of the small peptide fragments occupied positions distinguishable from one another and from AI and AIL Trypsin digestion yielded a single labeled product which traveled in the same position as 3-Val-10-Leu synthesized by the solid-phase technique. The single end product of leucine aminopeptidase digestion traveled in the same position as monoiodinated tyrosine. Chymotrypsin yielded two peptides: the major product was separable from All on paper electrophoresis and presumably consisted of the 1-4 sequence, and the minor product traveled in the AH position on both electrophoresis and chromatography and presumably consisted of the 1-8 sequence. Since all of the conversion experiments were analyzed by both techniques, it was possible to distinguish All from many of the probable peptide metabolites of AI and AIL Products of partial aminopeptidase digestion and of simultaneous digestion by multiple enzymes were not accounted for in these experiments.
HIGH VOLTAGE PAPER ELECTROPHORESIS

IN VITRO METABOLISM
Samples (10 ml) of blood were drawn from the antecubital veins of normotensive laboratory personnel into iced 10-ml glass tubes containing heparin (143 USP units). Samples were spun immediately at 4°C in a refrigerated centrifuge, and the plasma fraction was removed. Each 1-ml sample of plasma was diluted 1:3.5 with 0.1M Tris acetate buffer, pH 7.4, containing 0.1M NaCl (13). To 1.5 ml of diluted plasma was added 1.5 X 10 5 counts/min (approximately 0.15 pmoles) of 125 I-labeled peptide, giving a final concentration of 1 X 10 5 counts/mm mH (0.1 pmole/ml) of diluted plasma or 4.5 X 10 5 counts/min mH (0.45 pmoles/ml) of undiluted plasma. The mixture was incubated at 37°C, and 250-yyliter samples were removed at frequent intervals; 50 ^liters of each sample was immediately spotted on Whatman 3MM paper and subjected to electrophoresis as previously described. The remaining 200 ^liters from each sample was cooled to 4°C, treated with 3.4 mM 8-OH-quinoline (final concentration), and frozen. Each sample was passed through a 0.9 X 100-cm column of DEAE Sephadex A-25. Peptides were identified by comparison with known 125 I-AI, 125 I-AII, and trypsin, chymotrypsin, and leucine aminopeptidase digests of 125 I-AI as previously described.
IN VIVO METABOLISM
Eight mongrel dogs of both sexes weighing 15-20 kg were anesthetized with sodium pentobarbital (30 mg/kg, iv), placed on a respirator (Harvard), and maintained in deep anesthesia with halothane and oxygen. Each dog was given heparin (1,000 units/kg, iv). A Swan-Ganz catheter (14) was advanced into the pulmonary artery, as verified by the contour of the pressure tracing, then withdrawn until a typical right ventricular pressure tracing was obtained. The catheter was left in the right ventricle for the remainder of the experiment. Large-bore retrograde catheters were placed in the ascending and the abdominal aorta. Blood pressure was continuously monitored from the catheter Blood was collected in six sequential 12-ml samples from the ascending aorta at 5-second intervals. A series of plastic syringes connected via a manifold system and containing 2.6 DIM ethylenediaminetetraacetate (EDTA), 1.6 DIM dimercaptol, and 3.4 DIM 8-OH-quinoline (final concentration) was used for collection. Radioactive samples were processed and analyzed as previously described for plasma. Unlabeled plasma samples were subjected to radioimmunoassay for AI and All. The second and the third sequential samples obtained 5-15 seconds after injection represented one circulation through the lung as determined by the appearance time of radioactive material. To avoid interference with residual radioactive or immunoreactive material, at least 30 minutes was allowed to elapse between injections.
Results
PEPTIDE CHARACTERIZATION
Amino acid analyses were performed on a Beckman analyzer after hydrolysis with 5.7N HC1 for 24 hours at 110°C. Table 1 summarizes the results. Acid hydrolysis yielded the amino acids in the expected ratio.
One mg of each unlabeled peptide or 1 X 10 5 counts/min of iodinated peptide was dissolved in 30 //.liters of 0.1M acetic acid, spotted on Whatman 3MM paper, and subjected to descending chroma- tography in a butanol:acetic acid:water (4:1:5) system for 24 hours followed by electrophoresis in a second*dimension at 2,500 v for 1 hour at pH 3.6 in a pyridine acetate buffer. The paper was either stained with ninhydrin-collidine or cut into 1-cm squares and counted in a gamma counter. Each peptide produced a single spot with ninhydrincollidine stain or a single labeled spot.
BIOASSAY
In the rabbit aortic strip preparation AI had 5% of the activity of an equimolar amount of 1-Asp-AII. D-Pro-AI and D-Phe-AI had no detectable activity at 200 times the minimal effective dose of 1-Asp-AII; D-Ile-AI had no activity at 2,000 times the minimal effective dose of 1-Asp-AII. In halothane-anesthetized dogs, a 20-nmole dose of AI gave a rise in mean blood pressure of 31 ± 3 mm Hg. D-Phe-AI, DPro-AI, and D-Ile-AI in doses up to 400 nmoles gave no pressor response.
RADIOIMMUNOASSAY
The concentration of each peptide at 50% displacement and the percent cross-reactivity are summarized in Table 2 . All of the D-amino acid analogues of AI showed a low degree of crossreactivity with both anti-AI and anti-All. Neither they nor their conversion products could be measured in plasma by radioimmunoassay with anti-AI or anti-All. and its D-amino acid analogues is shown in Table 3 . present as small peptides; following injection of AI, D-Ile-AI, and D-Pro-AI, 10% was present as peptide metabolites. Figure 6 summarizes the results of a representative experiment with each peptide. Results from four experiments were reproducible within 10%. Analyses by electrophoresis and column chromatography were in close agreement. Due to the small molar quantity injected, no pressor response was seen with any of the peptides.
IN VITRO METABOLISM
The injection of a 3-fimole bolus of D-Phe-AI, DPro-AI, or D-Ile-AI did not produce a pressor response nor did it block the pulmonary conversion of a 30-nmole bolus of AI injected 30 seconds later. The concentration of All in the pulmonary effluent was 21.2 ± 1.7 (SE) pmoles/ml. The mean increase in systolic pressure was 30.6±3.2 (SE) mm Hg; the mean increase in diastolic pressure was 32.8 ±4.6 (SE) mm Hg. Both values were unchanged compared with the results of an injection of a similar dose of AI alone.
Discussion
In this study, conversion of AI and its D-amino acid-substituted analogues was followed using monoiodinated peptides as tracers. Peptide products of conversion were identified by comparison with standards on high-voltage paper electrophoresis and column chromatography on DEAE Sephadex. Synthetic AI, All, 3-Val-8-Phe, tyrosine, and the Damino acid-substituted analogues of AI were used as standards. D-Phe-AII, obtained by carboxypeptidase A digestion of D-Phe-AI, was the standard for identification of D-analogues of All. By analogy with AI and its D-analogues, it was assumed that DIle-AII and D-Pro-AII would migrate in the same position as D-Phe-AII and all-L-AII. Small peptide metabolites of AI and its D-analogues were prepared by trypsin, chymotrypsin, and leucine aminopeptidase digestion. These enzymes were chosen because they are well characterized, can be obtained in highly purified form, and have specificities similar to those of plasma angiotensinases (15, 16). All of the major peptides generated from both AI and its D-analogues in the course of the study corresponded to peaks defined by the peptide standards in both systems. Since all possible metabolic products were not investigated, some ambiguity in analysis remained. Nevertheless, the clear separation of All from AI and from the most probable metabolites allowed conversion to be identified with a high degree of confidence.
Monoiodinated AI was converted to All both in vivo and in vitro. Rates of conversion determined by this technique were similar to those reported previously for unlabeled or tritium-labeled AI (17, 18) . Pulmonary conversion was rapid, occurring to the extent of 70% in a single circulation time; plasma conversion was much slower, occurring with a half time of 6 minutes. The susceptibility of monoiodinated AI to plasma conversion in vitro has been demonstrated previously (12) . Since monoiodinated AI has been shown to retain substantial biologic activity (.19, 20) , the lack of pressor response to 12r 'I-AI in this study probably related to the Circulation Research, Vol. XXXII, April 1975 subpressor dose (100 pmoles) of peptide administered rather than to the inactivation of the peptide by the iodination procedure.
The monoiodinated angiotensins studied in these experiments were susceptible to degradation by angiotensinases both in vivo and in vitro. I-D-Phe-AI was degraded during a single passage through the lung. This finding bears out the earlier observation based on bioassay data that All survives the pulmonary circulation intact (21) . The relative slowness of angiotensinase action makes it unlikely that in vivo conversion can be masked by rapid destruction of the end product (All).
Modification of the structure of AI by single Damino acid substitutions has defined some of the structural requirements for angiotensin-converting Studies with artificial substrates in vitro confirm the observation that residues 1-7 of the AI molecule modify but are not absolutely required for the action of converting enzyme (22, 23) . Pulmonary and plasma converting enzyme cleave His-Leu from hippuryl-L-His-L-Leu in vitro although at a slower rate than from AI. The pulmonary enzyme cleaves the dipeptide from AI ten times as rapidly as it does from the artificial substrate (24) . The plasma enzyme cleaves dipeptides from a number of substrates of varied structure, indicating broad specificity (23) (24) (25) . The kinetics of cleavage with various substrates differ greatly. The behavior of the artificial substrates in vivo has not been evaluated.
None of the D-amino acid analogues of AI blocked the pulmonary conversion of AI when they were administered directly into the pulmonary circulation in 150:1 molar excess. Failure to block conversion was common to analogues which were susceptible to conversion and those which were not. This finding might relate to the large quantity of converting enzyme present in the lung (4, 17) or to the binding characteristics of peptides to the enzyme. D-amino acid substitutions in AI resulted in profound losses of biologic and immunologic activity. Parallel losses of biologic and immunologic activity have been reported for D-amino acid analogues of All (26) (27) (28) . The D-substituted peptides did not block the action of native All (29). These changes might reflect similarities in the structural requirements for binding to antibody and to receptor sites.
